Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $1,407,709.08 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 18,006 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08. Following the completion of the sale, the chief executive officer now directly owns 53,140 shares in the company, valued at $4,154,485.20. This trade represents a 25.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The shares were sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Price Performance

WGS stock opened at $96.57 on Thursday. The stock has a 50-day moving average price of $77.48 and a two-hundred day moving average price of $52.46. The company has a market cap of $2.65 billion, a PE ratio of -31.05 and a beta of 2.02. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 12-month low of $2.85 and a 12-month high of $98.87.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. During the same quarter last year, the firm posted ($0.82) earnings per share. GeneDx’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, research analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on WGS. TD Cowen lifted their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday. Wells Fargo & Company upped their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and an average price target of $70.67.

Institutional Trading of GeneDx

A number of institutional investors have recently added to or reduced their stakes in WGS. Renaissance Technologies LLC purchased a new position in GeneDx in the second quarter valued at about $2,362,000. Chartwell Investment Partners LLC purchased a new stake in shares of GeneDx during the 3rd quarter valued at about $1,722,000. Charles Schwab Investment Management Inc. lifted its position in GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock worth $6,240,000 after acquiring an additional 110,666 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in GeneDx in the 3rd quarter worth approximately $325,000. Finally, Lisanti Capital Growth LLC acquired a new stake in GeneDx in the third quarter valued at approximately $1,554,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.